Symatese and Evolus have established key partnerships and are now introducing Estyme®, four unique injectable hyaluronic acid (HA) gels in Europe.

Symatese has been a leading expert in the science of tissue regeneration, built on a technological platform which led to its next-generation hyaluronic acid–based injectable products for facial rejuvenation, based on COLD-X TECHNOLOGY by SYMATESE®, a cross-linking innovation which better preserves HA chains and enhances both performance and safety. Visit us at http://www.symatese.com.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers. Its mission is to become a global leader in aesthetics with a multi-product portfolio: Nuceiva® (prabotulinumtoxinA-xvfs), the brand name for its neurotoxin in international markets, and Estyme®, its collection of unique injectable HA gels in international markets. Visit us at www.evolus.com.